Stockreport

AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer [Yahoo! Finance]

AIM ImmunoTech Inc.  (AIM) 
PDF published on Roswell Park Comprehensive Cancer Center's Phase 1 study evaluating AIM ImmunoTech's drug Ampligen ® (also known as rintatolimod) as a component of a chemok [Read more]